Atrion Corporation

Report azionario NasdaqGS:ATRI

Capitalizzazione di mercato: US$809.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Atrion Performance degli utili passati

Criteri Il passato verificati 1/6

Gli utili di Atrion sono diminuiti a un tasso medio annuo di -11.4%, mentre il settore Medical Equipment ha visto gli utili crescere a un tasso medio annuo di 15.3%. I ricavi sono cresciuti crescere a un tasso medio annuo di 3.8%. Il ritorno sul capitale proprio di Atrion è 5.3% e ha margini netti di 6.9%.

Informazioni chiave

-11.40%

Tasso di crescita degli utili

-10.29%

Tasso di crescita dell'EPS

Medical Equipment Crescita del settore8.90%
Tasso di crescita dei ricavi3.82%
Rendimento del capitale proprio5.26%
Margine netto6.91%
Ultimo aggiornamento sugli utili30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Articolo di analisi • May 22

There May Be Some Bright Spots In Atrion's (NASDAQ:ATRI) Earnings

Soft earnings didn't appear to concern Atrion Corporation's ( NASDAQ:ATRI ) shareholders over the last week. We did...

Recent updates

Articolo di analisi • May 22

There May Be Some Bright Spots In Atrion's (NASDAQ:ATRI) Earnings

Soft earnings didn't appear to concern Atrion Corporation's ( NASDAQ:ATRI ) shareholders over the last week. We did...
Seeking Alpha • Mar 24

Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading

Summary Atrion Corporation, a healthcare company focused on fluid delivery products, has experienced a decline in revenue, profits, and cash flows. The drop in sales of fluid delivery products, which account for 42% of overall revenue, has severely impacted the company's top line. Despite the potential for improvement in the future, the stock is currently expensive compared to similar companies, warranting a cautious outlook and a downgrade to a 'sell' rating. Read the full article on Seeking Alpha
Articolo di analisi • Mar 23

Subdued Growth No Barrier To Atrion Corporation (NASDAQ:ATRI) With Shares Advancing 25%

Atrion Corporation ( NASDAQ:ATRI ) shareholders would be excited to see that the share price has had a great month...
Articolo di analisi • Feb 09

Here's Why Atrion (NASDAQ:ATRI) Can Manage Its Debt Responsibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Articolo di analisi • Jan 04

Atrion Corporation's (NASDAQ:ATRI) 26% Share Price Surge Not Quite Adding Up

Those holding Atrion Corporation ( NASDAQ:ATRI ) shares would be relieved that the share price has rebounded 26% in the...
Articolo di analisi • Sep 14

Atrion (NASDAQ:ATRI) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Articolo di analisi • Jul 18

Atrion (NASDAQ:ATRI) Will Want To Turn Around Its Return Trends

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Articolo di analisi • Apr 19

Be Wary Of Atrion (NASDAQ:ATRI) And Its Returns On Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Articolo di analisi • Oct 18

Atrion (NASDAQ:ATRI) May Have Issues Allocating Its Capital

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Seeking Alpha • Sep 08

Atrion: Attractively Priced For Exposure To Defensive Healthcare

Summary Artrion Corp. looks well positioned to continue delivering stable, predictable future cash flows. The stock is ideal for those seeking defensive characteristics into equity portfolios. Shares look attractively priced by our estimate of fair value. We rate ATRI a buy on a $632 valuation. Investment Summary Defensive healthcare looks well positioned to catch a bid in the current investment landscape as investors turn to factors of quality and resiliency. Earnings quality and fundamental momentum are paramount to overcome the deep drawdowns experienced across equity markets in FY22. With that, we look to Atrion Corporation (ATRI), a low volatility offering with extensive business history and deep customer networks. ATRI is ideal for investors seeking to add a defensive overlay to equity portfolios, and shares look attractively priced by our estimation. There's also the $2.15 recently declared dividend [+10.3% YoY] that is not discussed here. We rate ATRI a buy $632 price target. Atrion Q2 earnings: in-line with mature growth cycle ATRI came in with a strong set of numbers once again, with top-line growth of 14% printing quarterly revenue of $48.9 million ("mm"). The bolus of upside was driven by a 37% YoY gain in cardiovascular revenues, and 'other' revenues of 14%, offset by weakness in fluid delivery and ophthalmology, as seen in Exhibit 1. Meanwhile, COGS saw a 13% YoY gain due to the higher revenue volumes, whereas inventories lifted by ~690bps YoY. The spike in inventory value was driven by a 13% increase in raw material value, in-line with market trends and the commodity bull run of the past 12 months. This resulted in a gross profit of $20.8mm, up 16.6% YoY on a gross margin of 42.6%. Exhibit 1. The cardiovascular business continues to be the major performer on a sequential basis. Revenue split continues to shift toward a more even distribution towards cardiovascular. Cardiovascular margin is now ~37% of turnover in Q2 FY22. Note: Adapted from ATRI Q2 FY22 10-Q (Image: HB Insights. Data: ATRI) As seen in Exhibit 2, quarterly operating trends have been consistently buoyant for ATRI from FY15-date. Both turnover and operating profit have ticked up from low-points during the pandemic, whereas FCF [net of dividends] has been narrowing from FY20-date. We note the QoQ decline in FCF yield that investors have realized over this time, which, at face value looks to be quite alarming. Exhibit 2. Quarterly operating metrics demonstrate the resiliency on offer, with sales and pre-tax earnings both lifting back above pre-pandemic levels. Noted is the declining FCF yield on tighter FCF conversion, however, as we discuss below, this is coupled with favorable return on investment to justify the case. Note: [All earnings figures in $mm or %]. Quarterly operating measures are plotted against TTM FCF yield to observe effect of invested capital and return on invested capital. Calculations are made from GAAP earnings with no reconciliations. (Image: HB Insights; Data: ATRI SEC Filings) In light of the tightening FCF and FCF yields our findings illustrate that ATRI's return on investment has remained in the double digits across the examination period. Whilst FCF [net of dividends] has narrowed sequentially, ROIC has remained high and curled up since late FY21 on a TTM basis, as seen in Exhibit 3. This tells us the company is amid a strong capital budgeting cycle that has seen it invest more than it made during the period [in Q2 FY22 in particular]. The combination of negative FCF and rising return on investment is a favorable combination that is incredibly attractive in the current climate. Exhibit 3. Despite tightening FCF and realized FCF yields since FY15, ATRI continuously delivers double-digit return on investment that comfortably outpaces the WACC hurdle of 5% by ~2.8 turns. Note: All figures are in $mm or %. Invested capital is calculated with capitalized R&D investment from the income statement. (Image: HB Insights. Data: ATRI SEC filings) Valuation Shares are trading at 32x trailing earnings, ahead of the sector median's 26.6x. The stock is also priced at 4.5x book value, again a step above the sector's 2.2x. We need to understand what we're buying in ATRI. Valuation is a combination of investment, return on investment and earnings by our estimate - what's real, and what's expected.
Articolo di analisi • Aug 27

Atrion's (NASDAQ:ATRI) Upcoming Dividend Will Be Larger Than Last Year's

The board of Atrion Corporation ( NASDAQ:ATRI ) has announced that it will be paying its dividend of $2.15 on the 30th...
Seeking Alpha • Aug 22

Atrion raises dividend 10.3% to $2.15/share

Atrion (NASDAQ:ATRI) declares $2.15/share quarterly dividend, 10.3% increase from prior dividend of $1.95. Forward yield 1.38% Payable Sept. 30; for shareholders of record Sept. 15; ex-div Sept. 14. See ATRI Dividend Scorecard, Yield Chart, & Dividend Growth.
Articolo di analisi • Jul 18

Some Investors May Be Worried About Atrion's (NASDAQ:ATRI) Returns On Capital

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
Articolo di analisi • Jan 03

Atrion (NASDAQ:ATRI) Could Be Struggling To Allocate Capital

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Articolo di analisi • Nov 18

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation ( NASDAQ:ATRI ) will increase its dividend on the 15th of December to US$1.95. This takes the annual...
Articolo di analisi • Sep 03

Atrion's (NASDAQ:ATRI) Dividend Will Be Increased To US$1.95

Atrion Corporation's ( NASDAQ:ATRI ) dividend will be increasing to US$1.95 on 30th of September. This takes the annual...

Ripartizione dei ricavi e delle spese

Come Atrion guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storico di utili e ricavi

NasdaqGS:ATRI Ricavi, spese e utili (USD Millions )
DataRicaviUtiliSpese G+ASpese di R&S
30 Jun 2418213376
31 Mar 2417719327
31 Dec 2316919337
30 Sep 2316921336
30 Jun 2317127326
31 Mar 2317630326
31 Dec 2218435316
30 Sep 2218135316
30 Jun 2217934316
31 Mar 2217334296
31 Dec 2116533286
30 Sep 2115732266
30 Jun 2114831256
31 Mar 2114331245
31 Dec 2014832256
30 Sep 2015033256
30 Jun 2015535255
31 Mar 2015736256
31 Dec 1915537255
30 Sep 1915636255
30 Jun 1915636255
31 Mar 1915535255
31 Dec 1815234256
30 Sep 1815235256
30 Jun 1815034246
31 Mar 1814735246
31 Dec 1714737246
30 Sep 1714634236
30 Jun 1714633236
31 Mar 1714631227
31 Dec 1614328227
30 Sep 1614328226
30 Jun 1614228226
31 Mar 1614428226
31 Dec 1514629226
30 Sep 1514629227
30 Jun 1514529226
31 Mar 1514328226
31 Dec 1414128225
30 Sep 1414028225
30 Jun 1413728225
31 Mar 1413527214
31 Dec 1313227214
30 Sep 1312926204

Guadagni di qualità: ATRI ha guadagni di alta qualità.

Margine di profitto in crescita: Gli attuali margini di profitto netti di ATRI (6.9%) sono inferiori rispetto allo scorso anno (15.9%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di ATRI sono diminuiti del 11.4% all'anno negli ultimi 5 anni.

Accelerare la crescita: ATRI ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.

Guadagni vs Settore: ATRI ha avuto una crescita negativa degli utili ( -53.8% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Medical Equipment ( 14.8% ).

Rendimento del capitale proprio

ROE elevato: Il Return on Equity ( 5.3% ) di ATRI è considerato basso.

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2024/08/21 12:55
Prezzo dell'azione a fine giornata2024/08/21 00:00
Utili2024/06/30
Utili annuali2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Atrion Corporation è coperta da 1 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Norbert KalliwodaDr. Kalliwoda Research